Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.055
/ Totale documenti scaricati: 29.670.845

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.055
/ Totale documenti scaricati: 29.670.845

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Certifico 2000/2024: Informazione Utile


/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile



Vedi Promo Store fino al 30 Giugno -20% ticket "CERTIFICO20"
Slide background
Slide background
Certifico 2000/2024: Informazione Utile




/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile

/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *


Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile


/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20%

ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti Promo 2023

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *


Vedi Abbonamenti Promo 2022

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.


Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2022
Slide background
Certifico 2000/2021: Informazione Utile

/ Documenti disponibili: 43.055 *

/ Totale documenti scaricati: 29.670.845 *

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021

* Dati da Aprile 2014 alla data odierna.
Slide background
CEM4: certifico machinery directive

Il software per Direttiva macchine

da Marzo 2000

Promo Anniversary 21°
Slide background
Certifico 2000/2021: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021
Slide background
Certifico 2000/2020: Informazione Utile

Tutta la Documentazione presente è elaborata

o selezionata dalla nostra redazione su Standards riconosciuti.

Vedi i nostri abbonamenti e prodotti

Slide background








Europe, Rome

Medical devices | European Medicines Agency EMA

ID 12506 | | Visite: 3379 | News Marcatura CEPermalink: https://www.certifico.com/id/12506

MD EMA

Medical devices | European Medicines Agency EMA

ID 12506 | 04.01.2021 / Documento completo in allegato

Medical devices are products or equipment intended generally for a medical use and are regulated at Member State level. The Medical Devices and the In-Vitro Diagnostic Devices Regulations have introduced new responsibilities for the European Medicines Agency (EMA) and national competent authorities in the assessment of certain categories of medical device.

Medical devices in the EU have to undergo a conformity assessment to demonstrate that they meet legal requirements to ensure they are safe and perform as intended. EU Member States can designate accredited notified bodies to conduct conformity assessments.

The conformity assessment usually involves an audit of the manufacturer’s quality system and, depending on the type of device, a review of technical documentation from the manufacturer on the safety and performance of the device.

Manufacturers can place a CE (Conformité Européenne) mark on a medical device once it has passed a conformity assessment.

Medical devices legislation

The adoption in April 2017 of Regulation (EU) 2017/745 on Medical Devices (MDR) and Regulation (EU) 2017/746 on In-Vitro Diagnostic Devices (IVDR) changed the European legal framework for medical devices, introducing new responsibilities for EMA and for national competent authorities. Both Regulations entered into force in May 2017 and have a staggered transitional period.

On 23 April 2020, the European Parliament and the Council of the EU adopted a proposal to extend the transitional period of the Medical Devices Regulation by one year - until 26 May 2021.

This measure aims to avoid shortages of medical devices during the ongoing COVID-19 pandemic due to the limited capacity of national competent authorities or notified bodies to implement the Regulation.

Update: EMA will update its regulatory guidance in the first quarter of 2021 to reflect the new date of application of the Regulation.

For more information, see:

Regulation (EU) 2020/561 of the European Parliament and of the Council of 23 April 2020 amending Regulation (EU) 2017/745 on medical devices, as regards the dates of application of certain of its provisions

The MDR has a transitional period of four years and will fully apply from 26 May 2021. The IVDR has a transitional period of five years and will fully apply from 26 May 2022.

During the transitional period, manufacturers can opt to place medical devices on the market under the applicable EU Directives (93/42/EEC, 98/79/EC and 90/385/EEC) or under the new Regulations if they fully comply with these.

For guidance on the implementation of the new Regulations, see:

Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)
Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746) - tracked changes

Medicinal products that include a medical device (‘combination products’)

Some medicines are used in combination with a medical device, usually to enable the delivery of the medicine.

If the principle intended action of the combination product is achieved by the medicine, the entire product is regulated as a medicinal product under Directive 2001/83/EC or Regulation (EC) No 726/2004.

There are two types of combination:

integral: the medicinal product and device form a single integrated product e.g. pre-filled syringes and pens, patches for transdermal drug delivery and pre-filled inhalers;
co-packaged: the medicinal product and the device are separate items contained in the same pack e.g. reusable pen for insulin cartridges, tablet delivery system with controller for pain management.
Medical devices that are co-packaged or obtained separately must be CE marked in accordance with the medical device legislation.

Article 117 of the MDR introduced a new requirement for medicines with an integral device. From 26 May 2021, the marketing authorisation application should include a CE certificate for the device or, if it is not CE marked but would need to be certified if marketed separately, the applicant must include an opinion from a notified body on the conformity of the device. This requirement does not apply to Class I devices (non-sterile, non-measuring). For further information, see PDF iconQuestions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)

Role of EMA

The Agency is responsible for evaluating the quality, safety and efficacy of marketing authorisation applications assessed through the centralised procedure, including the safety and performance of the medical device in relation to its use with the medicinal product.

On 3 June 2019, EMA released for a 3-month public consultation a guideline on quality requirements for regulatory submissions for medicines that include a medical device (drug-device combinations). The device can be integral, co-packaged or obtained separately.

Quality requirements for drug-device combinations

The guideline clarifies expectations laid down in Directive 2001/83/EC and addresses the new obligations in the MDR, in particular the requirements under Article 117.

EMA will finalise the guideline before the entry into force of the MDR on 26 May 2021.

Medical devices with an ancillary medicinal substance

A medical device may contain an ancillary medicinal substance to support the proper functioning of the device. These products fall under the medical devices legislation and must be CE marked.

Examples of medical devices with an ancillary medicinal substance include drug-eluting stents, bone cement containing an antibiotic, catheters coated with heparin or an antibiotic agent and condoms coated with spermicides.

Role of EMA

Before it can issue a CE certificate, the notified body must seek a scientific opinion from the Agency on the quality and safety of the ancillary substance if it is derived from human blood or human plasma, or if it is within the scope of the centralised procedure for the authorisation of medicines.

The centralised procedure is compulsory for:

- human medicines containing a new active substance to treat:
- human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS);
- cancer;
- diabetes;
- neurodegenerative diseases;
- auto-immune and other immune dysfunctions;
viral diseases.
- medicines derived from biotechnology processes, such as genetic engineering;
- advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines;
- orphan medicines (medicines for rare diseases);
- veterinary medicines for use as growth or yield enhancers.

It is optional for other medicines:

- containing new active substances for indications other than those stated above;
- that are a significant therapeutic, scientific or technical innovation;
- whose authorisation would be in the interest of public or animal health at EU level.

Today, the great majority of new, innovative medicines pass through the centralised authorisation procedure in order to be marketed in the EU.

For other substances, the notified body can seek the opinion from a national competent authority or EMA e.g. in cases where the Agency has already evaluated a medicine containing the same medicinal substance.

EMA publishes consultation procedure public assessment reports (CPAR) on its scientific opinions.

For information on the consultation procedure to seek an EMA scientific opinion, see Consultation procedure for ancillary medicinal substances in medical devices.

Companion diagnostics ('in-vitro diagnostics')

A companion diagnostic is an in-vitro diagnostic test that supports the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment.

The In-Vitro Diagnostic Devices Regulation introduces a new classification system for companion diagnostics and the obligation to undergo a conformity assessment by a notified body.

Role of EMA

Before it can issue a CE certificate, the notified body must seek a scientific opinion from the Agency on the suitability of the companion diagnostic to the medicinal product concerned if:

the medicinal product falls exclusively within the scope of the centralised procedure for the authorisation of medicines, or
the medicinal product is already authorised through the centralised procedure, or
a marketing authorisation application for the medicinal product has been submitted through the centralised procedure.

For other substances, the notified body can seek the opinion from a national competent authority or EMA.

EMA will provide further information on the consultation procedure between the notified body and a competent authority or EMA.

Medical devices made of substances that are systemically absorbed

Some medical devices are made of substances that are absorbed by the human body to achieve their intended purpose.

These devices are normally introduced into the human body via an orifice or applied to the skin.

Role of EMA

Before it can issue a CE certificate, the notified body must seek a scientific opinion from EMA or a national competent authority on the compliance of the substance with the requirements laid down in Annex I to Directive 2001/83/EC.

EMA will provide further information on the consultation procedure between the notified body and a competent authority or EMA.

Borderline products

Borderline products are complex healthcare products for which there is uncertainty over which regulatory framework applies.

Common borderlines are between medicinal products, medical devices, cosmetics, biocidal products, herbal medicines and food supplements.

National competent authorities classify borderline products either as medicinal products or, for example, as medical devices on a case-by-case basis. This determines the applicable regulatory framework.

Applicants who are unclear on the correct classification of their product should consult a national competent authority and provide information on the product's composition and constituents, a scientific explanation of the mode of action and its intended purpose.

Role of EMA

The Medical Devices Regulation foresees that the European Commission may consult the Agency on products that borderline with medicines.

EMA's Innovation Task Force provides advice to medicine developers on eligibility to EMA procedures relating to the research and development of borderline products.

...

Fonte: EMA

Collegati

Tags: Marcatura CE Abbonati Marcatura CE Regolamento Dispositivi Medici

Ultimi inseriti

Decisione di esecuzione  UE  2025 792
Apr 25, 2025 15

Decisione di esecuzione (UE) 2025/792

Decisione di esecuzione (UE) 2025/792 ID 23873 | 25.04.2025 Decisione di esecuzione (UE) 2025/792 della Commissione, del 24 aprile 2025, relativa alla pubblicazione di un elenco indicante determinati valori di emissione di CO2 per costruttore nonché le emissioni specifiche medie di CO2 di tutti i… Leggi tutto
Apr 25, 2025 18

Decreto legislativo 21 novembre 2005 n. 285

Decreto legislativo 21 novembre 2005 n. 285 ID 23872 | 25.04.2025 Decreto legislativo 21 novembre 2005 n. 285Riordino dei servizi automobilistici interregionali di competenza statale. (GU n.6 del 09.01.2006 - SO n. 5) Entrata in vigore del provvedimento: 24/1/2006 __________ Testo consolidato 2021… Leggi tutto
Apr 25, 2025 19

Legge 11 agosto 2003 n. 218

Legge 11 agosto 2003 n. 218 ID 23871 | 25.04.2025 Legge 11 agosto 2003 n. 218Disciplina dell'attività di trasporto di viaggiatori effettuato mediante noleggio di autobus con conducente. (GU n.190 del 18.08.2003) ___________ Testo consolidato 2005 Modifiche / Abrogazioni: 01/12/2005 La Legge 28… Leggi tutto
Circolare MI n  12116 2025
Apr 24, 2025 18

Circolare Min Interno Prot. n. 12116 del 18 aprile 2025

Circolare Min Interno Prot. n. 12116 del 18 aprile 2025 ID 23870 | 25.04.2025 / In allegato Ministero dell'InternoAssolvimento dell’obbligo di esibizione dei documenti. Possibilità di utilizzare il documento informatico (Prot. 300/STRAD/1/0000012116.U/2025 del 18 aprile 2025) Sono pervenuti alcuni… Leggi tutto
Apr 23, 2025 101

Delibera n. 126 dell'11 marzo 2025

Delibera n. 126 dell'11 marzo 2025 ID 23867 | 23.04.2025 Regolamento sull’esercizio del potere di accertamento del possesso dei requisiti e del potere sanzionatorio dell’Autorità in materia di qualificazione delle stazioni appaltanti ai sensi dell’articolo 63, comma 11, e dell’allegato II.4,… Leggi tutto
Apr 23, 2025 89

Legge 11 febbraio 1980 n. 18

in News
Legge 11 febbraio 1980 n. 18 ID 23866 | 23.04.2025 Legge 11 febbraio 1980, n. 18Indennità di accompagnamento agli invalidi civili totalmente inabili. (GU n.44 del 14.02.1980)_________ Aggiornamenti all'atto 18/07/1984 DECRETO DEL PRESIDENTE DELLA REPUBBLICA 13 marzo 1984, n. 329 (in G.U.… Leggi tutto
Apr 23, 2025 93

Decreto 21 febbraio 2025

in News
Decreto 21 febbraio 2025 / Prestazione universale assistenziale persone anziane non autosufficienti ID 23865 | 23.04.2025 Decreto 21 febbraio 2025 Istituzione di una prestazione universale al fine di promuovere il progressivo potenziamento delle prestazioni assistenziali, per il sostegno della… Leggi tutto
Guidance on Dock shelters
Apr 23, 2025 99

Guidance on Dock shelters

Guidance on Dock shelters (FEM - October 2024) ID 23864 | 23.04.2025 / Attached Intention of this Guideline To provide users, architects, contractors and suppliers with an awareness of the benefits and specific characteristics of the different Dock shelter types used in the loading dock area.A dock… Leggi tutto

Ultimi Documenti Abbonati

Guidance on Dock shelters
Apr 23, 2025 99

Guidance on Dock shelters

Guidance on Dock shelters (FEM - October 2024) ID 23864 | 23.04.2025 / Attached Intention of this Guideline To provide users, architects, contractors and suppliers with an awareness of the benefits and specific characteristics of the different Dock shelter types used in the loading dock area.A dock… Leggi tutto
Circolare Prot  n  11456 del 14 aprile 2025
Apr 18, 2025 344

Circolare Prot. n. 11456 del 14 aprile 2025

Circolare Prot. n. 11456 del 14 aprile 2025 ID 23843 | 18.04.2025 / In allegato Parere relativo alle sanzioni previste dal Regolamento UE 1054/2020 in ordine alla sostituzione del tachigrafo di prima generazione con quello di nuova generazione ... Si fa riferimento alla nota del 27 marzo scorso di… Leggi tutto
Apr 17, 2025 359

UNI EN 13018:2016

UNI EN 13018:2016 / PND Esame visivo ID 23833 | 17.04.2025 / Preview allegata UNI EN 13018:2016 Prove non distruttive - Esame visivo - Principi generali Data disponibilità: 21 giugno 2016________ La norma specifica i principi generali per l'esame visivo, sia diretto sia remoto, qualora sia… Leggi tutto